The effects on hTERT gene expression is an additional mechanism of amino-bisphosphonates in prostatic cancer cells

European Journal of Pharmacology

Volumn 580, Issue 1-2, 2008, Pages 36-42

  Valenti, Maria Teresa ^a   Dalle Carbonare, Luca ^a   Bertoldo, Francesco ^a   Donatelli, Luca ^a   Lo Cascio, Vincenzo ^a  

^a UNIVERSITY OF VERONA   (Italy)

Author keywords

Bisphosphonates; Geranylgeraniol; hTERT gene; Prostatic cancer

Indexed keywords

ALENDRONIC ACID; BISPHOSPHONIC ACID DERIVATIVE; CLODRONIC ACID; GERANYLGERANIOL; GERANYLGERANYL PYROPHOSPHATE; MEVALONIC ACID; NERIDRONIC ACID; PAMIDRONIC ACID; TELOMERASE REVERSE TRANSCRIPTASE; ZOLEDRONIC ACID;

ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER CELL CULTURE; CELL VIABILITY; CONTROLLED STUDY; DOWN REGULATION; DRUG MECHANISM; DRUG TARGETING; ENZYME SUBSTRATE; GENE EXPRESSION; HUMAN; HUMAN CELL; PRIORITY JOURNAL; PROSTATE CARCINOMA;

ANTINEOPLASTIC AGENTS; CELL LINE, TUMOR; CELL SURVIVAL; DIPHOSPHONATES; DOWN-REGULATION; DRUG DELIVERY SYSTEMS; FARNESYLTRANSTRANSFERASE; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; MALE; MEVALONIC ACID; PROSTATIC NEOPLASMS; TELOMERASE;

EID: 37649006988     PISSN: 00142999     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ejphar.2007.10.067     Document Type: Article

References (30)

1. Amin D., Cornell S.A., Gustafson S.K., Needle S.J., Ullrich J.W., Bilder G., and Perrone M.H. Bisphosphonates used for the treatment of bone disorders inhibit squalene synthase and cholesterol biosynthesis. J. Lipid Res. 33 (1992) 1657-1663
2. Boisser S., Ferreras M., Peyruchaud O., Magnetto S., Ebetino F.H., Colombel M., Delmas P., Delaisse J.M., and Clezardin P. Bisphosphonates inhibit breast and prostate carcinoma cell invasion, an early even in the formation of bone metastases. Cancer Res. 60 (2000) 2949-2954
3. Brown J.E., Neville-Webbe H., and Coleman R. The role of bisphosphonates in breast and prostate cancer. Endocr.-Relat. Cancer 11 (2004) 207-224
4. Cong Y.S., Wen J., and Bacchetti S. The human telomerase catalytic subunit hTERT: organization of the gene and characterization of the promoter. Hum. Mol. Gen. 8 (1999) 137-142
5. Denoyelle C., Hong L., Vannier J.P., Soria J., and Soria C. New insights into the action of bisphosphonates zoledronic acid in breast cancer cells by dual RhoA-dependent and -independent effects. Br. J. Cancer 88 (2003) 1631-1640
6. Galasko C.S. Mechanisms of lytic and blastic metastatic disease of bone. Clin. Orthop. 169 (1982) 20-27
7. Goffinet M., Thoulouzan M., Pradines A., Lajoie-Mazenc I., Weinbaum C., Faye J.C., and Seronie-Vivien S. Zoledronic acid treatment impairs protein geranil-geranylation for biological effects in prostatic cells. BMC Cancer 15 (2006) 6-60
8. Guo C., Armbruster B.N., Price D.T., and Counter C.M. In vivo regulation of hTERT expression and telomerase activity by androgen. J. Urol. 170 (2003) 615-618
9. Jagdev S.P., Coleman R.E., Shipman C.M., Rostami H.A., and Croucher P.I. The bisphosphonate, zoledronic acid, induces apoptosis of breast cancer cells: evidence for Synergy with paclitaxel. Br. J. Cancer 84 (2001) 1126-1134
10. Latil A., Vidaud D., Valeri A., Fournier G., Vidaud M., Lidereau R., Cussenot O., and Biache I. hTERT expression correlates with MYC over-expression in human prostate cancer. Int. J. Cancer 89 (2000) 172-176
11. Lee Y.P., Schwartz E.M., Davies M., Jo M., Gates J., Zhang X., Wu J., and Lieberman J.R. Use of zoledronate to treat osteoblastic versus osteolytic lesions in a severe-combined-immunodeficient mouse model. Cancer Res. 62 (2002) 5564-5570
12. Lin X., Zhou C., Wang S., Wang D., Ma W., Liang X., Lin C., Wang Z., Li J., Guo S., Zhang Y., and Zhang S. Enhanced antitumor effect against human telomerase reverse transcriptase (hTERT) by vaccination with chemotactic-hTERT gene-modified tumor cell and the combination with anti-4-1BB monoclonal antibodies. Int. J. Cancer 119 (2006) 1886-1896
13. Lipton A. Zoledronate in the treatment of osteolytic bone metastases. Br. J. Clin. Pract. Symp. Suppl. 87 (1996) 21-22
14. Luckman S.P., Hughes D.E., Coxon F.P., Graham R., Russel G., and Rogers M.J. Nitrogen-containing bisphosphonates inhibit the mevalonate pathway and prevent post-traslational prenylation of GTP-binding proteins, including Ras. J. Bone Miner. Res. 13 (1998) 581-589
15. Marchetti A., Pellegrini C., Buttitta F., Falleni M., Romagnoli S., Felicioni L., Barassi F., Salvatore S., Chella A., Angeletti C.A., Roncalli M., Coggi G., and Bosari S. Prediction of survival in stage I lung carcinoma patients by telomerase function evaluation. Lab. Invest. 82 (2002) 729-736
16. Oades G.M., Senaratne S.G., Clarke I.A., Kirby R.S., and Colston K.W. Nitrogen containing bisphosphonates induce apoptosis and inhibit the mevalonate pathway, impairing Ras membrane localization in prostate cancer cells. J. Urol. 170 (2003) 246-252
17. Rogers M.J. New insights into the molecular mechanisms of action of bisphosphonates. Curr. Pharm. Des. 9 (2003) 2643-2658
18. Rogers M.J., Brown R.J., Hodkin V., Blackburn G.M., Russel R.G., and Watts D.J. Bisphosphonates are incorporated into adenine nucleotides by human aminoacyl-tRNA synthetase enzymes. Biochem. Biophys. Res. Commun. 224 (1996) 863-869
19. Rogers M.J., Gardon S., Benford H.L., Coxon F.P., Luckman S.P., Monkkonem J., and Frith J.C. Cellular and molecular mechanism of action of bisphosphonates. Cancer 88 (2000) 2961-2978
20. Saad F., Mckierman J., and Eastham J. Rationale for zoledronic acid therapy in men with hormone sensitivity prostate cancer with or without bone metastasis. Urol. Oncol. 24 (2006) 4-12
21. Santini D., Vincenzi B., Dicuonzo G., Avvisati G., Massacesi C., Battistoni F., Gavasci M., Rocci L., Tirindelli M.C., Altomare V., Tocchini M., Bonsignori M., and Tonini G. Zoledronic acid induces significant and long-lasting modifications of circulating angiogenic factors in cancer patients. Clin. Cancer Res. 9 (2003) 2893-2897
22. Sawaka K., Morishige K., Tahara M., Kawagishi R., Ikebuchi Y., Tasaka K., and Murata Y. Alendronate inhibits lysophosphatidic acid-induced migration of human ovarian cancer cells by attenuating the activation of rho. Cancer Res. 6 (2002) 6015-6020
23. Schmidt A., Rutledge S.J., Endo N., Opas E.E., Tanaka H., Wesolowski G., Leu C.T., Huang Z., Ramachandaran C., Rodan S.B., and Rodan G.A. Protein-tyrosine phosphatase activity regulates osteoclast formation and function: inhibition by alendronate. Proc. Natl. Acad. Sci. U.S.A. 93 (1996) 3068-3073
24. Schmidt B.M., Erdman Jr. J.W., and Lila M.A. Differential effects of blueberry proanthocyanidins on androgen sensitive and insensitive human prostate cancer cell lines. Cancer Lett. 231 (2006) 240-246
25. Stewart S.A., and Weinberg R.A. Senescence: does it all happen at the ends?. Oncogene 21 (2002) 627-630
26. Takai Y., Sasaki T., and Matozaki T. Small GTP-binding proteins. Phys. Rev. 81 (2001) 153-208
27. van Beek E.R., Cohen L.H., Leroy I.M., Ebetino F.H., Lowik C.W., and Papapoulos S.E. Differentiating the mechanisms of antiresorptive action of nitrogen containing bisphosphonates. Bone 33 (2003) 805-811
28. Vaziri H., and Benchimol S. Recostitution of telomerase activity in normal human cells leads to elongation of telomeres and extended replicative life span. Curr. Biol. 8 (1998) 279-282
29. Walter M., Davies J.P., and Ioannou Y.A. Telomerase immortalization upregulates Rab9 expression and restores LDL cholesterol egress from Niemann-Pick C1 late endosomes. J. Lipid Res. 44 (2003) 243-253
30. Webber M.M., Bello D., and Quadre S. Immortalized and tumorigenic adult human prostatic epithelial cell lines: characteristics and applications Part 2. Tumorigenic cell lines. Prostate 30 (1997) 58-64